Bepranemab clinical trials
Also written UCB0107.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How each study uses bepranemab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses bepranemab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear PalsyActive, not recruitingPhase 1UCB Biopharma SRLNCT04658199Written as UCB0107 (bepranemab)
- A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)CompletedPhase 2UCB Biopharma SRLNCT04867616Written as Bepranemab
- A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)CompletedPhase 1UCB Biopharma SRLNCT04185415Written as bepranemab
- A Study to Test the Safety and Tolerability and Pharmacokinetics of Single Doses of UCB0107 in Healthy Japanese SubjectsCompletedPhase 1UCB Biopharma S.P.R.L.NCT03605082Written as UCB0107
- A Study to Test the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of UCB0107 in Healthy Male SubjectsCompletedPhase 1UCB Biopharma S.P.R.L.NCT03464227Written as UCB0107
Codes
What other systems call bepranemab · ClinicalTrials.gg INT015888
- UNII (FDA) 9M1GV6L389BEPRANEMABOne source FDA
- NCI Thesaurus C174583BepranemabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 9M1GV6L389 | BEPRANEMAB | One source FDA |
| NCI Thesaurus | C174583 | Bepranemab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.